

# **ASN Kidney Week 2020 – Highlighted Sessions**

# **Presentations**

### ARPKD: Big Cysts in Little Kids

Thursday Oct 22, 10:30-12:30 am EDT

Moderators: Erum Hartung MD MS, Changlin Mei MD PhD

Speakers: Friedhelm Hildebrandt MD, Lisa Guay-Woodford MD, Ryuji Morizane MD PhD and Katherine

Dell MD

# Autosomal Dominant Polycystic Kidney Disease: Risk Assessment and Management

Thursday, Oct 22, 1:00-2:00 pm EDT Moderator: Fouad Chebib MD FASN

Speakers: Fouad Chebib MD FASN, Ron Gansevoort MD PhD FASN, Ronald D Perrone MD FASN

# Organelle Function and Dysfunction in Kidney Diseases

Saturday, Oct 24, 10:00-12:00 pm EDT

Moderators: Uta Erdbruegger MD and Jennie Lin MD MS

Speakers: Ying Maggie Chen MD PhD FASN, Ling Qi PhD, Reiko Inagi PhD and Whitney Besse MD

### Targeting Immunity and Inflammation in Polycystic Kidney Disease

Saturday, Oct 24, 10:00-12:00 pm EDT

Moderators: Michal Mrug MD and Jing Zhou MD PhD FASN

Speakers: Lloyd Cantley MD FASN, Kurt Zimmerman PhD, Katharina Hopp PhD, Dorien Peters PhD

## **Kidneyomics: From Cysts to Populations**

Saturday, Oct 24, 5:00-7:00 pm EDT

Moderators: Anna Kottgen MD MPH and Vishal Patel MD

Speakers: Yoshiharu Muto MD PhD, Kurt Zimmerman PhD, Laura Wilson PhD, Christopher Ward MBChB PhD, Sharon Barone MS, Bryce Rowan MS, Selvaraj Muthusamy MBBS PhD, Enrico Cocchi MD,

Dingxiao Liu MD and Russell Thomson PhD



# Check out the PKD Foundation's poster!



### Design and basic characteristics of a national patient registry in ADPKD

Elise Hoover MPH, David Baron PhD, Beverly A Benson PhD, Berenice Gitomer PhD, Klee Kleber, Amy Manelli, Michal Mrug MD, Meyeon Park MD, Chris Rusconi PhD, Stephen L Seliger MD MS, Ronald D Perrone MD and Terry J Watnick MD, *PO1575* 

# Posters from our current grantees and Scientific Advisory Committee

Benefit of Tolvaptan on Time to ESRD for Patients with Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD): A Disease Progression Model

Terry J Watnick MD, PO1540

<u>Biological Efficacy and Safety of Niacinamide in Patients with Autosomal Dominant Polycystic Kidney Disease</u>
Alan SL Yu MB BChir, *PO1579* 

Cardiac Dysfunction in Pkd1-Deficient Mice Is Associated with Metabolic Rewiring

Alessandra Boletta PhD, PO1508

<u>Characterization of the Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Response in Autosomal Dominant Polycystic Kidney Disease</u>

Maria V Irazabal MD, PO1555

<u>Correlation of baseline urinary metabolic biomarkers with ADPKD severity in the TAME-PKD study participants</u> Terry J Watnick MD, *PO1568* 

<u>Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults with Autosomal Dominant</u>
<u>Polycystic Kidney Disease (ADPKD): Design and Baseline Characteristics of Participants</u>

Kristen L Nowak PhD and Berenice Gitomer PhD, PO1580

<u>Cyst-Lumen Renal Stones in Mice Compound Heterozygous for Hypomorphic Pkd1V and Pkd1RC Alleles</u> Stephen C Parnell PhD, Feng Qian PhD, *PO1557* 

<u>Defective NAD+ Homeostasis in ADPKD and the Effects of PC1CTT on Redox Modulation and Disease</u>
<u>Progression</u>

Laura Onuchic MD, PO1506

Dietary Protein Load Increases Kidney Macrophage and Accelerates Polycystic Kidney Disease

Takamitsu Saigusa MD, PO1556



# <u>The Effect of Trehalose on Autophagy-Related Proteins and Cyst Growth in a Hypomorphic Pkd1 Mouse Model of Autosomal Dominant Polycystic Kidney Disease (ADPKD)</u>

Katharina Hopp PhD, PO1548

# Mechanisms of Tethered-Ligand Mediated Polycystin 1 GPCR Signaling

Robin L Maser PhD, PO1510

### Outcome of Hospitalized ESRD-COVID-19 (C19) Infected Patients

Frederic F Rahbari-Oskoui MD, P00735

### Overweight and Obesity Are Predictors of Pain in the HALT-PKD Studies

Kristen L Nowak PhD, Berenice Gitomer PhD and Alan SL Yu MB BChir, PO1570

### PKD1 Compared with PKD2 Genotype and Cardiac Hospitalizations in the HALT-PKD Studies

Kristen L Nowak PhD, Berenice Gitomer PhD and Alan SL Yu MB BChir, PO1525

## Primary Cilia Defects Reflect Specific Bone Cell Activity in Human ADPKD Osteoblast Cells

Berenice Gitomer PhD, PO1553

## STAGED-PKD: An Enriched, Seamless, Two-Stage Study for Venglustat Assessment in ADPKD

Michal Mrug MD, PO1577

# STAGED-PKD: Patient Enrichment and Modeling-Driven Efficient ADPKD Trial Design

Michal Mrug MD, PO1578

#### Suppressed Autophagic Flux in the Heart in a Hypomorphic Pkd1 Mouse Model of ADPKD

Katharina Hopp PhD, PO1549

### **Volume Progression and Imaging Classification of Polycystic Liver in ADPKD**

Alan SL Yu MB BChir and Michal Mrug MD, PO1572

We have done our best to include mention of all polycystic kidney disease-related sessions, as well as abstracts from our 2018-2020 grantee cohorts and SAC members. Please forgive the oversight if we have missed anyone. This is a living document and can be updated. Please email <a href="mailto:eliseh@pkdcure.org">eliseh@pkdcure.org</a> with corrections or additions that you believe relevant to the PKD researcher and clinician communities. Thank you in advance for your help, and enjoy Kidney Week 2020!